Healthcare has started getting the type of attention it deserves

The pharmaceutical sector in India is poised to carve out a remarkable growth curve, and as Nikhil Chopra, CEO and Whole Time Director, J B Chemicals and Pharmaceuticals Ltd., points out in this interview, their company is ready to spin bigger benefits with a well-planned strategy

- 

Nikhil Chopra

CEO and Whole Time Director J B Chemicals and Pharmaceuticals Ltd

In your opinion, how is the current situation of the Indian pharmaceutical industry?

India is the pharmacy capital of the world. We provide world-class medicines at affordable prices to India and the world. Especially, in India we are privileged that affordable and quality medicine access is marking new benchmarks thanks to the strength and capabilities of indigenous pharmaceutical companies and their manufacturing prowess. Further, the Indian pharmaceutical industry has evolved tremendously in the last couple of decades. With the pandemic, the awareness about overall wellbeing will certainly gather momentum.

The pharmaceutical sector plays a critical and pivotal role in addressing these changing needs and also plays an indispensable role in improving healthcare access. Even in the Union Budget 2021, the pharmaceutical and healthcare sector managed to get the necessary attention. Overall, the pharmaceutical industry will witness a growth of 9-10% in the coming years and the Indian pharmaceutical industry is poised to become one of the leading partners.

What are the factors that boosted the company’s margin ratios in FY20 as compared to FY19?

The business continued to show encouraging momentum and registered a very healthy growth rate in Q3. India business continues to witness a positive trend in the chronic segment and we are among the fastest-growing companies in IPM. In the post-pandemic world, the Indian pharmaceutical industry got its due recognition and an opportunity to showcase its strength in helping the world heal from the daunting challenge.